These are designed to stimulate the immune system to fight the tumour, but only 20% of people with lung cancer respond, as tumours often block immune cells from entering. The researchers combined a ...

Receiving an mRNA COVID-19 vaccine within 100 days of starting ICI therapy may improve overall survival in some patients with cancer.

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the ...

A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer.R ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how molecular glue triggers degradation of PHGDH by ...

New evidence shows that extended estrogen suppression treatment using an aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe; it does not increase the risk of ...

Hepatocellular carcinoma or HCC is the most commonly observed form of liver cancer and the fourth leading cause of ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment ...

BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant ... efficacy of BAY 2927088 ...